Skip to Content

Join the 'Champix' group to help and get support from people like you.

Champix News

Most Elderly Smokers Don't Use Anti-Smoking Meds After Heart Attack

Posted 14 Nov 2016 by Drugs.com

SUNDAY, Nov. 13, 2016 – Many elderly smokers who've had a heart attack fail to fill prescriptions for medications designed to help them quit smoking, a new study finds. "These findings come as no surprise for geriatricians and health care professionals who face on a daily basis the challenges of recognizing and managing the complexity of caring for older adults," said Dr. Gisele Wolf-Klein, who reviewed the new findings. She directs geriatric education at Northwell Health in Great Neck, N.Y. She noted that elderly patients face many challenges, such as "multiple medical conditions, which often include depression and forgetfulness." That can make it tough for them to initiate and stick with a quit-smoking regimen such as medications, lozenges or patches, Wolf-Klein said. The new study was led by Dr. Neha Pagidipati of Duke University Medical Center in Durham, N.C. It was scheduled for ... Read more

Related support groups: Wellbutrin, Bupropion, Smoking, Heart Attack, Chantix, Contrave, Wellbutrin XL, Smoking Cessation, Wellbutrin SR, Nicotine, Zyban, Myocardial Infarction, Champix, Nicorette, Nicoderm CQ, Budeprion, Nicotrol Inhaler, Aplenzin, Budeprion XL, Commit

Most Smokers Don't Stick With E-Cigarettes

Posted 31 May 2016 by Drugs.com

TUESDAY, May 31, 2016 – Some smokers turn to e-cigarettes with the hope that the electronic nicotine delivery devices will help them give up regular cigarettes. But new research suggests that for most smokers, e-cigarettes aren't an acceptable alternative. The good news from the study is that e-cigarettes helped at least a small group of smokers quit tobacco cigarettes. Ideally, study lead author Terry Pechacek said, e-cigarettes would be both appealing and less dangerous than traditional cigarettes. "Even if they're only half as risky, there would be a huge public health benefit if we could switch 40 million smokers to them," he said. But the study suggests smokers who've tried them are saying "that's possible but we're not there yet," said Pechacek, professor and interim division director of Health Management and Policy at Georgia State University in Atlanta. For the study, the ... Read more

Related support groups: Wellbutrin, Bupropion, Smoking, Chantix, Wellbutrin XL, Smoking Cessation, Wellbutrin SR, Nicotine, Zyban, Champix, Nicorette, Nicoderm CQ, Budeprion, Nicotrol Inhaler, Aplenzin, Budeprion XL, Commit, Varenicline, Zyban Advantage Pack, Buproban

No Link Between Anti-Smoking Drugs, Mental Health Issues: Study

Posted 23 Apr 2016 by Drugs.com

FRIDAY, April 22, 2016 – The anti-smoking drugs Chantix (varenicline) and Wellbutrin (bupropion) don't appear to raise the risk of serious mental health disorders such as depression, anxiety and suicidal thoughts, a new study suggests. "Clinical guidelines recommend that the most effective way to give up smoking is smoking cessation medication and counseling. However, smokers do not use these services enough, in part due to concerns that the medications may not be safe," said lead author Dr. Robert Anthenelli, professor of psychiatry at University of California, San Diego. The new study, published April 22 in The Lancet, should help ease those concerns for patients, the researchers said. The study was requested by the U.S. Food and Drug Administration due to concerns about the safety of the drugs used to help people quit smoking. Funding was provided by drug makers Pfizer (which makes ... Read more

Related support groups: Depression, Anxiety, Anxiety and Stress, Wellbutrin, Major Depressive Disorder, Social Anxiety Disorder, Bupropion, Smoking, Chantix, Schizophrenia, Contrave, Wellbutrin XL, Smoking Cessation, Wellbutrin SR, Agitation, Nicotine, Psychosis, Eating Disorder, Zyban, Agitated State

No Clear Winner Seen Among Stop-Smoking Aids in Study

Posted 26 Jan 2016 by Drugs.com

TUESDAY, Jan. 26, 2016 – If you're trying to quit smoking, using the nicotine patch, the drug Chantix, or a combination of the patch and lozenges all appear to work equally well, researchers report. "To our surprise, all three treatments were essentially identical," said lead author Dr. Michael Fiore, director of the University of Wisconsin Center for Tobacco Research and Intervention in Madison. Results of the three approaches did not differ significantly at either six months or a year, the investigators found. At six months, the quit rate was 23 percent for the patch, 24 percent for Chantix, and 27 percent for the combination of patch and lozenges. At a year, the quit rate was 21 percent, 19 percent and 20 percent, respectively, the findings showed. In the past, Chantix (varenicline) or the combination of the nicotine patch and nicotine lozenges were shown in studies to be more ... Read more

Related support groups: Wellbutrin, Bupropion, Smoking, Chantix, Wellbutrin XL, Smoking Cessation, Wellbutrin SR, Nicotine, Zyban, Champix, Nicorette, Nicoderm CQ, Budeprion, Nicotrol Inhaler, Aplenzin, Budeprion XL, Commit, Varenicline, Zyban Advantage Pack, Buproban

Anti-Smoking Drug Chantix May Help Women Sooner Than Men

Posted 13 Oct 2015 by Drugs.com

TUESDAY, Oct. 13, 2015 – An effective prescription drug used to help people quit smoking initially helps women more than men, new research suggests. The study, from Yale School of Medicine, found that Chantix (varenicline) helped women more than men for the first year of treatment. After a year, however, the anti-smoking medication worked equally well for both men and women. "Studies show that women have a harder time quitting smoking than men, even as quitting has shown greater benefits to women's cardiovascular and respiratory health," Sherry McKee, professor of psychiatry and lead researcher of Yale's Specialized Center of Research, said in a university news release. "With this first comprehensive analysis of sex differences in the effectiveness of this drug, now women and their health care providers can better decide how to successfully quit and live longer, healthier lives," she ... Read more

Related support groups: Smoking, Chantix, Smoking Cessation, Champix, Varenicline

Lung Cancer Patients Who Quit Smoking Live Longer

Posted 16 Jul 2015 by Drugs.com

THURSDAY, July 16, 2015 – Lung cancer patients live longer if they quit smoking around the time of their cancer diagnosis, a new study finds. Researchers looked at 250 lung cancer patients who were smokers and were referred to a program to help them stop smoking. Fifty had recently quit smoking, and 71 had quit smoking soon after being referred to the tobacco cessation program. Those who quit smoking shortly before or after they learned they had lung cancer lived an average of 28 months. Those who continued to smoke lived an average of 18 months, the study found. Even patients with advanced lung cancer gained extra survival time if they quit smoking, the study in the July issue of the Journal of Thoracic Oncology showed. The researchers also found that patients who didn't quit smoking but continued their attempts to quit may also live longer. However, death rates for those who quit and ... Read more

Related support groups: Wellbutrin, Bupropion, Smoking, Chantix, Wellbutrin XL, Smoking Cessation, Wellbutrin SR, Nicotine, Lung Cancer, Zyban, Champix, Nicorette, Nicoderm CQ, Budeprion, Nicotrol Inhaler, Aplenzin, Budeprion XL, Commit, Varenicline, Zyban Advantage Pack

Smoking, Preterm Births Increase a Woman's Heart Disease Risk

Posted 9 Jul 2015 by Drugs.com

THURSDAY, July 9, 2015 – Women who smoke and have had a premature baby are at significantly higher risk for heart disease, a new study finds. Researchers examined data from more than 900,000 mothers and found that those who smoked and also had a preterm birth were nearly three-and-a-half times more likely to develop heart disease than nonsmokers who had full-term births. That risk is 29 percent higher than the risk associated with either smoking or preterm birth alone, according to the study published July 9 in the European Journal of Preventive Cardiology. The risk of heart disease was even higher among mothers who smoked and had multiple or extremely premature births. "Fertility treatment is pushing up rates of preterm birth and smoking in pregnant women remains high, so knowledge of the impact of these conditions on [heart disease] is important for prevention efforts. Our research ... Read more

Related support groups: Wellbutrin, Bupropion, Heart Disease, Smoking, Heart Attack, Chantix, Wellbutrin XL, Smoking Cessation, Wellbutrin SR, Nicotine, Zyban, Myocardial Infarction, Champix, Nicorette, Coronary Artery Disease (CAD), Nicoderm CQ, Budeprion, Nicotrol Inhaler, Aplenzin, Premature Labor

As U.S. Smoking Rate Drops, Smokers More Likely to Quit: Study

Posted 25 Jun 2015 by Drugs.com

THURSDAY, June 25, 2015 – As the number of smokers in the United States dwindles, those who still light up are becoming less attached to the habit and more likely to try quitting, a new study has found. These findings run counter to the theory of "hardening," which has held that as smoking rates decline those who still smoke will be increasingly committed to their habit, said study author Margarete Kulik, a postdoctoral fellow with the Center for Tobacco Control Research and Education at the University of California, San Francisco. "The assumption is as smoking prevalence decreases, those smokers who are left will be the hardcore smokers who are unable or unwilling to quit," Kulik said. "We found out that there is not hardening. There is softening. There is actually more quitting, and people smoke less." The study was published online June 24 in the journal Tobacco Control. Dr. Norman ... Read more

Related support groups: Wellbutrin, Bupropion, Smoking, Chantix, Wellbutrin XL, Smoking Cessation, Wellbutrin SR, Nicotine, Zyban, Champix, Nicorette, Nicoderm CQ, Budeprion, Nicotrol Inhaler, Aplenzin, Budeprion XL, Commit, Varenicline, Zyban Advantage Pack, Buproban

Ban Flavoring, Ads for E-Cigarettes, Doctors' Group Says

Posted 22 Apr 2015 by Drugs.com

WEDNESDAY, April 22, 2015 – The U.S. Food and Drug Administration should ban flavorings and television ads for e-cigarettes, a prominent physicians' organization says. There is scant evidence that e-cigarettes help people quit smoking, as claimed by manufacturers. And the chemicals used in these devices may be harmful to both smokers and bystanders, said Ryan Crowley, senior associate for health policy at the American College of Physicians (ACP). "There are over 7,000 different flavorings in e-cigarettes, and the evidence shows that young people are attracted to these products because of the flavors," Crowley said. "There are also concerns that there are harmful chemicals in the flavorings themselves." Crowley added that calling for a ban on TV ads for e-cigarettes follows ACP's continuing policy supporting bans on all tobacco advertising. The organization also recommends taxing ... Read more

Related support groups: Wellbutrin, Bupropion, Smoking, Chantix, Wellbutrin XL, Smoking Cessation, Wellbutrin SR, Nicotine, Zyban, Champix, Nicorette, Nicoderm CQ, Budeprion, Nicotrol Inhaler, Aplenzin, Budeprion XL, Commit, Varenicline, Zyban Advantage Pack, Buproban

Two-Pronged Program Looks Best for Helping Smokers Quit

Posted 19 Oct 2014 by Drugs.com

FRIDAY, Oct. 17, 2014 – A combination of counseling and medication greatly increases smokers' chances of quitting, according to new research. The study included 1,560 adult smokers in England who made at least one attempt to quit over six months. About 45 percent used no aids to help them quit, while about 5 percent used prescription medication (nicotine replacement therapy, bupropion or varenicline) in combination with behavioral counseling. Another 21 percent used prescription medication with brief advice, and about 30 percent used over-the-counter nicotine replacement products. After six months, 23 percent of the participants were no longer smoking. Those who used the medication/counseling method were nearly three times more likely to quit than those who did not use medication or counseling. Taking a prescription medication with brief advice was also more effective than unaided ... Read more

Related support groups: Chantix, Smoking Cessation, Nicotine, Zyban, Champix, Nicorette, Nicoderm CQ, Nicotrol Inhaler, Commit, Varenicline, Habitrol, Nicotrol TD, Nicorelief, Nicorette DS, Nicotrol NS, ProStep

Combo Approach May Work Best for Smokers Looking to Quit

Posted 8 Jul 2014 by Drugs.com

TUESDAY, July 8, 2014 – Combining two anti-smoking approaches – the medication Chantix and nicotine patches – improves the odds you'll quit smoking over the short term, a new industry-funded study suggests. "The combination appears to be safe, although further studies are needed to confirm this," said Dr. Coenie Koegelenberg, an associate professor of pulmonology with Stellenbosch University and Tygerberg Academic Hospital in South Africa. Although the dual treatment costs more than either agent separately, Koegelenberg said the drugs typically aren't used for long and will reduce overall health costs if smokers succeed in quitting. Chantix, known by the generic name varenicline, appears to help people stop smoking by interfering with the way that nicotine stimulates the brain. However, smokers who take Chantix may be at higher risk for heart attacks and stroke compared to those who ... Read more

Related support groups: Smoking, Chantix, Smoking Cessation, Nicotine, Champix, Nicorette, Nicoderm CQ, Nicotrol Inhaler, Commit, Varenicline, Habitrol, Nicotrol TD, Nicorelief, Nicorette DS, Nicotrol NS, ProStep

Psychiatric Side Effects of Chantix to be Reviewed in Fall: FDA

Posted 28 Apr 2014 by Drugs.com

MONDAY, April 28, 2014 – The mental health risks associated with the anti-smoking drug Chantix will be reviewed at a public meeting scheduled for October, the U.S. Food and Drug Administration says. The meeting will feature a panel of experts who will discuss the psychiatric and behavioral side effects of the pill and how best to manage them, the agency announced Friday, The New York Times reported. In 2009, the FDA ordered drug maker Pfizer to add a black box label – the strongest safety warning – to Chantix after it was linked to hostility, aggression, depression and suicidal thoughts. There were dozens of reports of suicide and suicidal behavior among people taking the drug. Pfizer was also told to conduct further studies to assess the extent of these side effects. The company recently provided the FDA with new data about the anti-smoking drug. "Pfizer has proposed an update to ... Read more

Related support groups: Chantix, Smoking Cessation, Champix, Varenicline

Drug Duo Might Help Smokers Quit Better Than Single Med

Posted 7 Jan 2014 by Drugs.com

TUESDAY, Jan. 7, 2014 – Two drugs in combination might be better than one when it comes to helping hardcore smokers quit, at least in the short term, a new study suggests. The drugs – varenicline (sold under the brand name Chantix) and bupropion (Zyban) – taken together increase the rates of quitting over 12 weeks compared with Chantix alone, the researchers found. After a year, however, relapse rates were similar using both approaches. "We believe this evidence strongly supports the idea that varenicline helps everybody quit," said lead researcher Dr. Jon Ebbert, a professor of medicine at the Mayo Clinic in Rochester, Minn. "But for heavier smokers and more dependent smokers, combination therapy with varenicline plus bupropion will increase quit rates more than varenicline alone." "This is how we are going to treat patients," he said. Combination therapy works better than a single ... Read more

Related support groups: Wellbutrin, Bupropion, Chantix, Wellbutrin XL, Smoking Cessation, Wellbutrin SR, Zyban, Champix, Budeprion, Aplenzin, Budeprion XL, Zyban Advantage Pack, Varenicline, Buproban, Budeprion SR

Stop-Smoking Drug Chantix May Carry Heart Risks, FDA Warns

Posted 13 Dec 2012 by Drugs.com

THURSDAY, Dec. 13 – People who take the prescription quit-smoking drug Chantix may be at higher risk for cardiovascular problems, and doctors should weigh the risks of the drug against it benefits, the U.S. Food and Drug Administration said. A major review of clinical trials that compared patients who took Chantix (varenicline) to patients who took a placebo found that those who took the drug had slightly higher rates of serious cardiovascular events such as nonfatal heart attack, nonfatal stroke and cardiovascular-related death, according to an FDA drug safety communication released Wednesday. However, the increased risk among people taking Chantix was not statistically significant, which means that it is unclear whether their increased risk was due to the drug or due to chance, the agency added. Chantix works by blocking the effects of nicotine on the brain. The FDA first alerted the ... Read more

Related support groups: Chantix, Smoking Cessation, Champix, Varenicline

FDA Drug Safety Communication: Safety Review Update of Chantix (varenicline) and Risk of Cardiovascular Adverse Events

Posted 13 Dec 2012 by Drugs.com

This update is in follow-up to the Drug Safety Communications issued on 6/16/20111 and 7/22/20112. Safety Announcement Additional Information for Patients Additional Information for Health Care Professionals Data Summary References   Safety Announcement [12-12-2012] The U.S. Food and Drug Administration (FDA) is informing the public about the results of a large, combined analysis (called a meta-analysis) of clinical trials that compared patients who received the smoking cessation drug Chantix (varenicline) to patients who received a placebo (an inactive treatment). FDA required the manufacturer of Chantix to conduct the meta-analysis to further evaluate the cardiovascular safety of the drug, and believes it is important to let health care professionals and patients know about the results of this study. FDA first notified the public about a possible increased risk of cardiovascular ... Read more

Related support groups: Chantix, Smoking Cessation, Champix, Varenicline

Page 1 2 Next

Ask a Question

Further Information

Related Condition Support Groups

Smoking Cessation

Champix Patient Information at Drugs.com